{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T04:36:43Z","timestamp":1719635803836},"reference-count":166,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDS"],"published-print":{"date-parts":[[2021,3,12]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Despite substantial improvements over the years, diabetes mellitus is still\nassociated with cardiovascular disease, heart failure, and excess mortality.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The objective of this article is to examine existing data on the reduction of cardiovascular\nmorbidity and mortality in diabetes. Control of glycemia, lipid levels, and blood pressure are described\nin brief. The main scope of this article is, however, to review the glucose-independent cardiovascular\neffect of antidiabetic pharmacological agents (mainly other than insulin).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>The article is a narrative review based on recently published reviews and meta-analyses\ncomplemented with data from individual trials, when relevant.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results and Discussion:<\/jats:title>\n<jats:p>Older data suggest a cardioprotective role of metformin (an inexpensive\nand safe drug); a role to date not convincingly challenged. The cardiovascular effects of thiazolidinediones,\nsulphonylurea, and glinides are debatable. Recent large-scale cardiovascular outcome\ntrials suggest a neutral profile of dipeptidyl peptidase 4 inhibitors, yet provide compelling evidence\nof cardioprotective effects of glucagon-like 1 receptor antagonists and sodium-glucose transporter\n2 inhibitors.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Metformin may have a role in primary and secondary prevention of cardiovascular disease;\nglucagon-like 1 receptor antagonists and sodium-glucose co-transporter 2 inhibitors play a\nrole in secondary prevention of atherosclerotic cardiovascular disease. Sodium-glucose transporter\n2 inhibitors have a role to play in both primary and secondary prevention of heart failure; yet, they\ncarry a small risk of the potentially dangerous adverse effect, euglycemic diabetic ketoacidosis.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1574886315666200902154736","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T16:54:47Z","timestamp":1599152087000},"page":"32-51","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cardiovascular Effects of Hypoglycemic Agents in Diabetes Mellitus"],"prefix":"10.2174","volume":"16","author":[{"given":"Anna","family":"Pietraszek","sequence":"first","affiliation":[{"name":"Steno Diabetes Center North Jutland, Aalborg University Hospital, Aalborg, Aalborg, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","volume":"157","author":"Saeedi P.","year":"2019","unstructured":"Saeedi P.; Petersohn I.; Salpea P.; Malanda B.; Karuranga S.; Unwin N.; Colagiuri S.; Guariguata L.; Motala A.A.; Ogurtsova K.; Shaw J.E.; Bright D.; Williams R.; Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9 edition. Diabetes Res Clin Pract 2019,157,107843","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=2","year":"2016","unstructured":"Global Health Estimates 2016: Disease burden by Cause, Age, Sex, by Country and by Region, 2000-2016 World Health Organization 2016","journal-title":"World Health Organization"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","volume":"375","author":"Sarwar N.","year":"2010","unstructured":"Sarwar N.; Gao P.; Seshasai S.R.; Gobin R.; Kaptoge S.; Di Angelantonio E.; Ingelsson E.; Lawlor D.A.; Selvin E.; Stampfer M.; Stehouwer C.D.; Lewington S.; Pennells L.; Thompson A.; Sattar N.; White I.R.; Ray K.K.; Danesh J.; Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010,375(9733),2215-2222","journal-title":"Lancet"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1001\/archinte.167.11.1145","volume":"167","author":"Franco O.H.","year":"2007","unstructured":"Franco O.H.; Steyerberg E.W.; Hu F.B.; Mackenbach J.; Nusselder W.; Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med 2007,167(11),1145-1151","journal-title":"Arch Intern Med"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1007\/s00125-013-3063-1","volume":"56","author":"Lind M.","year":"2013","unstructured":"Lind M.; Garcia-Rodriguez L.A.; Booth G.L.; Cea-Soriano L.; Shah B.R.; Ekeroth G.; Lipscombe L.L.; Mortality trends in patients with and without diabetes in Ontario, Canada and the UK from 1996 to 2009: a population-based study. Diabetologia 2013,56(12),2601-2608","journal-title":"Diabetologia"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1056\/NEJMoa1408214","volume":"371","author":"Lind M.","year":"2014","unstructured":"Lind M.; Svensson A.M.; Kosiborod M.; Gudbj\u00f6rnsdottir S.; Pivodic A.; Wedel H.; Dahlqvist S.; Clements M.; Rosengren A.; Glycemic control and excess mortality in type 1 diabetes. N Engl J Med 2014,371(21),1972-1982","journal-title":"N Engl J Med"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1056\/NEJMc1706292","volume":"377","author":"Rawshani A.","year":"2017","unstructured":"Rawshani A.; Rawshani A.; Gudbj\u00f6rnsdottir S.; Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. N Engl J Med 2017,377(3),300-301","journal-title":"N Engl J Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0140-6736(18)31506-X","volume":"392","author":"Rawshani A.","year":"2018","unstructured":"Rawshani A.; Sattar N.; Franz\u00e9n S.; Rawshani A.; Hattersley A.T.; Svensson A.M.; Eliasson B.; Gudbj\u00f6rnsdottir S.; Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet 2018,392(10146),477-486","journal-title":"Lancet"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1056\/NEJMoa1504347","volume":"373","author":"Tancredi M.","year":"2015","unstructured":"Tancredi M.; Rosengren A.; Svensson A.M.; Kosiborod M.; Pivodic A.; Gudbj\u00f6rnsdottir S.; Wedel H.; Clements M.; Dahlqvist S.; Lind M.; Excess Mortality among Persons with Type 2 Diabetes. N Engl J Med 2015,373(18),1720-1732","journal-title":"N Engl J Med"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.annepidem.2018.08.015","volume":"28","author":"Alva M.L.","year":"2018","unstructured":"Alva M.L.; Hoerger T.J.; Zhang P.; Cheng Y.J.; State-level diabetes-attributable mortality and years of life lost in the United States. Ann Epidemiol 2018,28(11),790-795","journal-title":"Ann Epidemiol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1161\/CIRCULATIONAHA.114.014796","volume":"132","author":"Cavender M.A.","year":"2015","unstructured":"Cavender M.A.; Steg P.G.; Smith S.C.; Eagle K.; Ohman E.M.; Goto S.; Kuder J.; Im K.; Wilson P.W.; Bhatt D.L.; Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Circulation 2015,132(10),923-931","journal-title":"Circulation"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/0735-1097(93)90348-5","volume":"21","author":"Granger C.B.","year":"1993","unstructured":"Granger C.B.; Califf R.M.; Young S.; Candela R.; Samaha J.; Worley S.; Kereiakes D.J.; Topol E.J.; Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. J Am Coll Cardiol 1993,21(4),920-925","journal-title":"J Am Coll Cardiol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s11606-015-3556-3","volume":"31","author":"Rana J.S.","year":"2016","unstructured":"Rana J.S.; Liu J.Y.; Moffet H.H.; Jaffe M.; Karter A.J.; Diabetes and Prior Coronary Heart Disease are Not Necessarily Risk Equivalent for Future Coronary Heart Disease Events. J Gen Intern Med 2016,31(4),387-393","journal-title":"J Gen Intern Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1016\/S0140-6736(15)60401-9","volume":"385","author":"Dinesh Shah A.","year":"2015","unstructured":"Dinesh Shah A.; Langenberg C.; Rapsomaniki E.; Denaxas S.; Pujades-Rodriguez M.; Gale C.P.; Deanfield J.; Smeeth L.; Timmis A.; Hemingway H.; Type 2 diabetes and incidence of a wide range of cardiovascular diseases: a cohort study in 1\u00b79 million people. Lancet 2015,385(Suppl. 1),S86","journal-title":"Lancet"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"671","DOI":"10.2337\/dc16-2016","volume":"40","author":"Dauriz M.","year":"2017","unstructured":"Dauriz M.; Targher G.; Laroche C.; Temporelli P.L.; Ferrari R.; Anker S.; Coats A.; Filippatos G.; Crespo-Leiro M.; Mebazaa A.; Piepoli M.F.; Maggioni A.P.; Tavazzi L.; Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From the ESC-HFA Heart Failure Long-Term Registry. Diabetes Care 2017,40(5),671-678","journal-title":"Diabetes Care"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/ejhf.679","volume":"19","author":"Targher G.","year":"2017","unstructured":"Targher G.; Dauriz M.; Laroche C.; Temporelli P.L.; Hassanein M.; Seferovic P.M.; Drozdz J.; Ferrari R.; Anker S.; Coats A.; Filippatos G.; Crespo-Leiro M.G.; Mebazaa A.; Piepoli M.F.; Maggioni A.P.; Tavazzi L.; In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. Eur J Heart Fail 2017,19(1),54-65","journal-title":"Eur J Heart Fail"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dci18-0033","volume":"41","author":"Davies M.J.","year":"2018","unstructured":"Davies M.J.; D\u2019Alessio D.A.; Fradkin J.; Kernan W.N.; Mathieu C.; Mingrone G.; Rossing P.; Tsapas A.; Wexler D.J.; Buse J.B.; Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018,41(12),2669-2701","journal-title":"Diabetes Care"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"Cosentino F.","year":"2020","unstructured":"Cosentino F.; Grant P.J.; Aboyans V.; Bailey C.J.; Ceriello A.; Delgado V.; Federici M.; Filippatos G.; Grobbee D.E.; Hansen T.B.; Huikuri H.V.; Johansson I.; J\u00fcni P.; Lettino M.; Marx N.; Mellbin L.G.; \u00d6stgren C.J.; Rocca B.; Roffi M.; Sattar N.; Seferovi\u0107 P.M.; Sousa-Uva M.; Valensi P.; Wheeler D.C.; 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020,41(2),255-323","journal-title":"Eur Heart J"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1800256","volume":"379","author":"Rawshani A.","year":"2018","unstructured":"Rawshani A.; Rawshani A.; Franz\u00e9n S.; Sattar N.; Eliasson B.; Svensson A.M.; Zethelius B.; Miftaraj M.; McGuire D.K.; Rosengren A.; Gudbj\u00f6rnsdottir S.; Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2018,379(7),633-644","journal-title":"N Engl J Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1016\/S0140-6736(17)30819-X","volume":"389","year":"2017","unstructured":"Smoking prevalence and attributable disease burden in 195 countries and territories, 1990-2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet 2017,389(10082),1885-1906","journal-title":"Lancet"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1001\/archinternmed.2012.3130","volume":"172","author":"Sluik D.","year":"2012","unstructured":"Sluik D.; Buijsse B.; Muckelbauer R.; Kaaks R.; Teucher B.; Johnsen N.F.; Tj\u00f8nneland A.; Overvad K.; Ostergaard J.N.; Amiano P.; Ardanaz E.; Bendinelli B.; Pala V.; Tumino R.; Ricceri F.; Mattiello A.; Spijkerman A.M.; Monninkhof E.M.; May A.M.; Franks P.W.; Nilsson P.M.; Wennberg P.; Rolandsson O.; Fagherazzi G.; Boutron-Ruault M.C.; Clavel-Chapelon F.; Casta\u00f1o J.M.; Gallo V.; Boeing H.; N\u00f6thlings U.; Physical Activity and Mortality in Individuals With Diabetes Mellitus: A Prospective Study and Meta-analysis. Arch Intern Med 2012,172(17),1285-1295","journal-title":"Arch Intern Med"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1056\/NEJMoa1800389","volume":"378","author":"Estruch R.","year":"2018","unstructured":"Estruch R.; Ros E.; Salas-Salvad\u00f3 J.; Covas M.I.; Corella D.; Ar\u00f3s F.; G\u00f3mez-Gracia E.; Ruiz-Guti\u00e9rrez V.; Fiol M.; Lapetra J.; Lamuela-Raventos R.M.; Serra-Majem L.; Pint\u00f3 X.; Basora J.; Mu\u00f1oz M.A.; Sorl\u00ed J.V.; Mart\u00ednez J.A.; Fit\u00f3 M.; Gea A.; Hern\u00e1n M.A.; Mart\u00ednez-Gonz\u00e1lez M.A.; Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med 2018,378(25),e34","journal-title":"N Engl J Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1056\/NEJM200105033441801","volume":"344","author":"Tuomilehto J.","year":"2001","unstructured":"Tuomilehto J.; Lindstr\u00f6m J.; Eriksson J.G.; Valle T.T.; H\u00e4m\u00e4l\u00e4inen H.; Ilanne-Parikka P.; Kein\u00e4nen-Kiukaanniemi S.; Laakso M.; Louheranta A.; Rastas M.; Salminen V.; Uusitupa M.; Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001,344(18),1343-1350","journal-title":"N Engl J Med"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(17)33102-1","volume":"391","author":"Lean M.E.","year":"2018","unstructured":"Lean M.E.; Leslie W.S.; Barnes A.C.; Brosnahan N.; Thom G.; McCombie L.; Peters C.; Zhyzhneuskaya S.; Al-Mrabeh A.; Hollingsworth K.G.; Rodrigues A.M.; Rehackova L.; Adamson A.J.; Sniehotta F.F.; Mathers J.C.; Ross H.M.; McIlvenna Y.; Stefanetti R.; Trenell M.; Welsh P.; Kean S.; Ford I.; McConnachie A.; Sattar N.; Taylor R.; Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 2018,391(10120),541-551","journal-title":"Lancet"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa1212914","volume":"369","author":"Wing R.R.","year":"2013","unstructured":"Wing R.R.; Bolin P.; Brancati F.L.; Bray G.A.; Clark J.M.; Coday M.; Crow R.S.; Curtis J.M.; Egan C.M.; Espeland M.A.; Evans M.; Foreyt J.P.; Ghazarian S.; Gregg E.W.; Harrison B.; Hazuda H.P.; Hill J.O.; Horton E.S.; Hubbard V.S.; Jakicic J.M.; Jeffery R.W.; Johnson K.C.; Kahn S.E.; Kitabchi A.E.; Knowler W.C.; Lewis C.E.; Maschak-Carey B.J.; Montez M.G.; Murillo A.; Nathan D.M.; Patricio J.; Peters A.; Pi-Sunyer X.; Pownall H.; Reboussin D.; Regensteiner J.G.; Rickman A.D.; Ryan D.H.; Safford M.; Wadden T.A.; Wagenknecht L.E.; West D.S.; Williamson D.F.; Yanovski S.Z.; Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013,369(2),145-154","journal-title":"N Engl J Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"Stratton I.M.","year":"2000","unstructured":"Stratton I.M.; Adler A.I.; Neil H.A.; Matthews D.R.; Manley S.E.; Cull C.A.; Hadden D.; Turner R.C.; Holman R.R.; Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000,321(7258),405-412","journal-title":"BMJ"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/BF00400195","volume":"34","year":"1991","unstructured":"UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 1991,34(12),877-890","journal-title":"Diabetologia"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"Holman R.R.","year":"2008","unstructured":"Holman R.R.; Paul S.K.; Bethel M.A.; Matthews D.R.; Neil H.A.; 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008,359(15),1577-1589","journal-title":"N Engl J Med"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa0808431","volume":"360","author":"Duckworth W.","year":"2009","unstructured":"Duckworth W.; Abraira C.; Moritz T.; Reda D.; Emanuele N.; Reaven P.D.; Zieve F.J.; Marks J.; Davis S.N.; Hayward R.; Warren S.R.; Goldman S.; McCarren M.; Vitek M.E.; Henderson W.G.; Huang G.D.; Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009,360(2),129-139","journal-title":"N Engl J Med"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa1806802","volume":"380","author":"Reaven P.D.","year":"2019","unstructured":"Reaven P.D.; Emanuele N.V.; Wiitala W.L.; Bahn G.D.; Reda D.J.; McCarren M.; Duckworth W.C.; Hayward R.A.; Intensive Glucose Control in Patients with Type 2 Diabetes - 15-Year Follow-up. N Engl J Med 2019,380(23),2215-2224","journal-title":"N Engl J Med"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","author":"Patel A.","year":"2008","unstructured":"Patel A.; MacMahon S.; Chalmers J.; Neal B.; Billot L.; Woodward M.; Marre M.; Cooper M.; Glasziou P.; Grobbee D.; Hamet P.; Harrap S.; Heller S.; Liu L.; Mancia G.; Mogensen C.E.; Pan C.; Poulter N.; Rodgers A.; Williams B.; Bompoint S.; de Galan B.E.; Joshi R.; Travert F.; Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008,358(24),2560-2572","journal-title":"N Engl J Med"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1056\/NEJMoa1407963","volume":"371","author":"Zoungas S.","year":"2014","unstructured":"Zoungas S.; Chalmers J.; Neal B.; Billot L.; Li Q.; Hirakawa Y.; Arima H.; Monaghan H.; Joshi R.; Colagiuri S.; Cooper M.E.; Glasziou P.; Grobbee D.; Hamet P.; Harrap S.; Heller S.; Lisheng L.; Mancia G.; Marre M.; Matthews D.R.; Mogensen C.E.; Perkovic V.; Poulter N.; Rodgers A.; Williams B.; MacMahon S.; Patel A.; Woodward M.; Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 2014,371(15),1392-1406","journal-title":"N Engl J Med"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"21i","DOI":"10.1016\/j.amjcard.2007.03.003","volume":"99","author":"Buse J.B.","year":"2007","unstructured":"Buse J.B.; Bigger J.T.; Byington R.P.; Cooper L.S.; Cushman W.C.; Friedewald W.T.; Genuth S.; Gerstein H.C.; Ginsberg H.N.; Goff D.C.; Grimm R.H.; Margolis K.L.; Probstfield J.L.; Simons-Morton D.G.; Sullivan M.D.; Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007,99(12A),21i-33i","journal-title":"Am J Cardiol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"Gerstein H.C.","year":"2008","unstructured":"Gerstein H.C.; Miller M.E.; Byington R.P.; Goff D.C.; Bigger J.T.; Buse J.B.; Cushman W.C.; Genuth S.; Ismail-Beigi F.; Grimm R.H.; Probstfield J.L.; Simons-Morton D.G.; Friedewald W.T.; Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008,358(24),2545-2559","journal-title":"N Engl J Med"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2337\/dc15-2283","volume":"39","year":"2016","unstructured":"Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes. Diabetes Care ACCORD Study Group2016,39(5),701-708","journal-title":"Diabetes Care"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1007\/s00125-009-1470-0","volume":"52","author":"Turnbull F.M.","year":"2009","unstructured":"Turnbull F.M.; Abraira C.; Anderson R.J.; Byington R.P.; Chalmers J.P.; Duckworth W.C.; Evans G.W.; Gerstein H.C.; Holman R.R.; Moritz T.E.; Neal B.C.; Ninomiya T.; Patel A.A.; Paul S.K.; Travert F.; Woodward M.; Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009,52(11),2288-2298","journal-title":"Diabetologia"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"Dormandy J.A.","year":"2005","unstructured":"Dormandy J.A.; Charbonnel B.; Eckland D.J.; Erdmann E.; Massi-Benedetti M.; Moules I.K.; Skene A.M.; Tan M.H.; Lef\u00e8bvre P.J.; Murray G.D.; Standl E.; Wilcox R.G.; Wilhelmsen L.; Betteridge J.; Birkeland K.; Golay A.; Heine R.J.; Kor\u00e1nyi L.; Laakso M.; Mok\u00e1n M.; Norkus A.; Pirags V.; Podar T.; Scheen A.; Scherbaum W.; Schernthaner G.; Schmitz O.; Skrha J.; Smith U.; Taton J.; Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005,366(9493),1279-1289","journal-title":"Lancet"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/0735-1097(95)00126-K","volume":"26","author":"Malmberg K.","year":"1995","unstructured":"Malmberg K.; Ryd\u00e9n L.; Efendic S.; Herlitz J.; Nicol P.; Waldenstr\u00f6m A.; Wedel H.; Welin L.; Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995,26(1),57-65","journal-title":"J Am Coll Cardiol"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4158\/EP.10.S2.13","volume":"10","author":"Malmberg K.","year":"2004","unstructured":"Malmberg K.; Role of insulin-glucose infusion in outcomes after acute myocardial infarction: the diabetes and insulin-glucose infusion in acute myocardial infarction (DIGAMI) study Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists Endocr Pract 2004,10(Suppl12),13-6","journal-title":"Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists Endocr Pract"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/eurheartj\/ehi199","volume":"26","author":"Malmberg K.","year":"2005","unstructured":"Malmberg K.; Ryd\u00e9n L.; Wedel H.; Birkeland K.; Bootsma A.; Dickstein K.; Efendic S.; Fisher M.; Hamsten A.; Herlitz J.; Hildebrandt P.; MacLeod K.; Laakso M.; Torp-Pedersen C.; Waldenstr\u00f6m A.; Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005,26(7),650-661","journal-title":"Eur Heart J"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1008862","volume":"364","author":"Rao Kondapally Seshasai S.","year":"2011","unstructured":"Rao Kondapally Seshasai S.; Kaptoge S.; Thompson A.; Di Angelantonio E.; Gao P.; Sarwar N.; Whincup P.H.; Mukamal K.J.; Gillum R.F.; Holme I.; Nj\u00f8lstad I.; Fletcher A.; Nilsson P.; Lewington S.; Collins R.; Gudnason V.; Thompson S.G.; Sattar N.; Selvin E.; Hu F.B.; Danesh J.; Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011,364(9),829-841","journal-title":"N Engl J Med"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/S0002-9149(99)80683-3","volume":"75","year":"1995","unstructured":"Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995,75(14),894-903","journal-title":"Am J Cardiol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1056\/NEJMoa052187","volume":"353","author":"Nathan D.M.","year":"2005","unstructured":"Nathan D.M.; Cleary P.A.; Backlund J.Y.; Genuth S.M.; Lachin J.M.; Orchard T.J.; Raskin P.; Zinman B.; Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005,353(25),2643-2653","journal-title":"N Engl J Med"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.2337\/dc08-0107","volume":"31","author":"Soedamah-Muthu S.S.","year":"2008","unstructured":"Soedamah-Muthu S.S.; Chaturvedi N.; Witte D.R.; Stevens L.K.; Porta M.; Fuller J.H.; Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS). Diabetes Care 2008,31(7),1360-1366","journal-title":"Diabetes Care"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/aje\/kwm096","volume":"166","author":"Shankar A.","year":"2007","unstructured":"Shankar A.; Klein R.; Klein B.E.; Moss S.E.; Association between glycosylated hemoglobin level and cardiovascular and all-cause mortality in type 1 diabetes. Am J Epidemiol 2007,166(4),393-402","journal-title":"Am J Epidemiol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S0002-9343(99)00126-6","volume":"106","author":"Chen Y.T.","year":"1999","unstructured":"Chen Y.T.; Vaccarino V.; Williams C.S.; Butler J.; Berkman L.F.; Krumholz H.M.; Risk factors for heart failure in the elderly: a prospective community-based study. Am J Med 1999,106(6),605-612","journal-title":"Am J Med"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"e002560","DOI":"10.1161\/CIRCHEARTFAILURE.115.002560","volume":"9","author":"Kristensen S.L.","year":"2016","unstructured":"Kristensen S.L.; Preiss D.; Jhund P.S.; Squire I.; Cardoso J.S.; Merkely B.; Martinez F.; Starling R.C.; Desai A.S.; Lefkowitz M.P.; Rizkala A.R.; Rouleau J.L.; Shi V.C.; Solomon S.D.; Swedberg K.; Zile M.R.; McMurray J.J.; Packer M.; Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail PARADIGM-HF Investigators and Committees2016,9(1),e002560","journal-title":"Circ Heart Fail"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","volume":"380","author":"Mihaylova B.","year":"2012","unstructured":"Mihaylova B.; Emberson J.; Blackwell L.; Keech A.; Simes J.; Barnes E.H.; Voysey M.; Gray A.; Collins R.; Baigent C.; The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012,380(9841),581-590","journal-title":"Lancet"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","volume":"371","author":"Kearney P.M.","year":"2008","unstructured":"Kearney P.M.; Blackwell L.; Collins R.; Keech A.; Simes J.; Peto R.; Armitage J.; Baigent C.; Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008,371(9607),117-125","journal-title":"Lancet"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","volume":"137","author":"Giugliano R.P.","year":"2018","unstructured":"Giugliano R.P.; Cannon C.P.; Blazing M.A.; Nicolau J.C.; Corbal\u00e1n R.; \u0160pinar J.; Park J.G.; White J.A.; Bohula E.A.; Braunwald E.; Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From improve-it (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators2018,137(15),1571-1582","journal-title":"Circulation"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","volume":"5","author":"Sabatine M.S.","year":"2017","unstructured":"Sabatine M.S.; Leiter L.A.; Wiviott S.D.; Giugliano R.P.; Deedwania P.; De Ferrari G.M.; Murphy S.A.; Kuder J.F.; Gouni-Berthold I.; Lewis B.S.; Handelsman Y.; Pineda A.L.; Honarpour N.; Keech A.C.; Sever P.S.; Pedersen T.R.; Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol 2017,5(12),941-950","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jama.2014.18574","volume":"313","author":"Emdin C.A.","year":"2015","unstructured":"Emdin C.A.; Rahimi K.; Neal B.; Callender T.; Perkovic V.; Patel A.; Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 2015,313(6),603-615","journal-title":"JAMA"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1056\/NEJMoa021778","volume":"348","author":"Gaede P.","year":"2003","unstructured":"Gaede P.; Vedel P.; Larsen N.; Jensen G.V.; Parving H.H.; Pedersen O.; Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003,348(5),383-393","journal-title":"N Engl J Med"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1007\/s00125-016-4065-6","volume":"59","author":"G\u00e6de P.","year":"2016","unstructured":"G\u00e6de P.; Oellgaard J.; Carstensen B.; Rossing P.; Lund-Andersen H.; Parving H.H.; Pedersen O.; Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21\u00a0years follow-up on the Steno-2 randomised trial. Diabetologia 2016,59(11),2298-2307","journal-title":"Diabetologia"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1007\/s00125-018-4642-y","volume":"61","author":"Oellgaard J.","year":"2018","unstructured":"Oellgaard J.; G\u00e6de P.; Rossing P.; R\u00f8rth R.; K\u00f8ber L.; Parving H.H.; Pedersen O.; Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21\u00a0years of follow-up in the randomised Steno-2 study. Diabetologia 2018,61(8),1724-1733","journal-title":"Diabetologia"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1161\/CIRCULATIONAHA.118.037454","volume":"139","author":"Rawshani A.","year":"2019","unstructured":"Rawshani A.; Rawshani A.; Sattar N.; Franz\u00e9n S.; McGuire D.K.; Eliasson B.; Svensson A.M.; Zethelius B.; Miftaraj M.; Rosengren A.; Gudbj\u00f6rnsdottir S.; Relative Prognostic Importance and Optimal Levels of Risk Factors for Mortality and Cardiovascular Outcomes in Type 1 Diabetes Mellitus. Circulation 2019,139(16),1900-1912","journal-title":"Circulation"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12933-015-0296-y","volume":"14","author":"Gyberg V.","year":"2015","unstructured":"Gyberg V.; De Bacquer D.; De Backer G.; Jennings C.; Kotseva K.; Mellbin L.; Schnell O.; Tuomilehto J.; Wood D.; Ryd\u00e9n L.; Amouyel P.; Bruthans J.; Conde A.C.; Cifkova R.; Deckers J.W.; De Sutter J.; Dilic M.; Dolzhenko M.; Erglis A.; Fras Z.; Gaita D.; Gotcheva N.; Goudevenos J.; Heuschmann P.; Laucevicius A.; Lehto S.; Lovic D.; Mili\u010di\u0107 D.; Moore D.; Nicolaides E.; Oganov R.; Paj\u0105k A.; Pogosova N.; Reiner Z.; Stagmo M.; St\u00f6rk S.; Tokg\u00f6zo\u011flu L.; Vulic D.; Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. Cardiovasc Diabetol EUROASPIRE Investigators2015,14,133","journal-title":"Cardiovasc Diabetol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1007\/s00125-017-4318-z","volume":"60","author":"Bailey C.J.","year":"2017","unstructured":"Bailey C.J.; Metformin: historical overview. Diabetologia 2017,60(9),1566-1576","journal-title":"Diabetologia"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1056\/NEJM199508313330902","volume":"333","author":"DeFronzo R.A.","year":"1995","unstructured":"DeFronzo R.A.; Goodman A.M.; Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995,333(9),541-549","journal-title":"N Engl J Med"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/MOL.0000000000000532","volume":"29","author":"Jenkins A.J.","year":"2018","unstructured":"Jenkins A.J.; Welsh P.; Petrie J.R.; Metformin, lipids and atherosclerosis prevention. Curr Opin Lipidol 2018,29(4),346-353","journal-title":"Curr Opin Lipidol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/sj.ijo.0803695","volume":"32","author":"Golay A.","year":"2008","unstructured":"Golay A.; Metformin and body weight International journal of obesity 2008,32(1),61-72","journal-title":"International journal of obesity"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"791","DOI":"10.2337\/diab.24.9.791","volume":"24","author":"Assan R.","year":"1975","unstructured":"Assan R.; Heuclin C.; Girard J.R.; LeMaire F.; Attali J.R.; Phenformin-induced lactic acidosis in diabetic patients. Diabetes 1975,24(9),791-800","journal-title":"Diabetes"},{"key":"ref=63","year":"2020","unstructured":"UK Electronic Medicines Compendium (EMC)2020"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jdiacomp.2017.11.003","volume":"32","author":"Crandall J.P.","year":"2018","unstructured":"Crandall J.P.; Metformin and vitamin B12-What\u2019s missing from this picture? J Diabetes Complications 2018,32(2),129","journal-title":"J Diabetes Complications"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2165\/11536790-000000000-00000","volume":"33","author":"Lalau J.D.","year":"2010","unstructured":"Lalau J.D.; Lactic acidosis induced by metformin: incidence, management and prevention. Drug Saf 2010,33(9),727-740","journal-title":"Drug Saf"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2337\/diacare.28.3.539","volume":"28","author":"Cryer D.R.","year":"2005","unstructured":"Cryer D.R.; Nicholas S.P.; Henry D.H.; Mills D.J.; Stadel B.V.; Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study. Diabetes Care 2005,28(3),539-543","journal-title":"Diabetes Care"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0953-6205(02)00131-0","volume":"13","author":"Rachmani R.","year":"2002","unstructured":"Rachmani R.; Slavachevski I.; Levi Z.; Zadok B.; Kedar Y.; Ravid M.; Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. Eur J Intern Med 2002,13(7),428","journal-title":"Eur J Intern Med"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2337\/diacare.22.6.925","volume":"22","author":"Stang M.","year":"1999","unstructured":"Stang M.; Wysowski D.K.; Butler-Jones D.; Incidence of lactic acidosis in metformin users. Diabetes Care 1999,22(6),925-927","journal-title":"Diabetes Care"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"CD002967","DOI":"10.1002\/14651858.CD002967.pub3","author":"Salpeter S.R.","year":"2010","unstructured":"Salpeter S.R.; Greyber E.; Pasternak G.A.; Salpeter E.E.; Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010(4),CD002967","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","volume":"352","year":"1998","unstructured":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet UK Prospective Diabetes Study (UKPDS) Group1998,352(9131),854-865","journal-title":"Lancet"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"Turner R.","year":"1998","unstructured":"Turner R.; Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet UK Prospective Diabetes Study (UKPDS) Group1998,352(9131),837-853","journal-title":"Lancet"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"CD002966","DOI":"10.1002\/14651858.CD002966.pub3","author":"Saenz A.","year":"2005","unstructured":"Saenz A.; Fernandez-Esteban I.; Mataix A.; Ausejo M.; Roque M.; Moher D.; Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005(3),CD002966","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1001\/archinternmed.2009.20","volume":"169","author":"Kooy A.","year":"2009","unstructured":"Kooy A.; de Jager J.; Lehert P.; Bets D.; Wulffel\u00e9 M.G.; Donker A.J.; Stehouwer C.D.; Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 2009,169(6),616-625","journal-title":"Arch Intern Med"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"e1001204","DOI":"10.1371\/journal.pmed.1001204","volume":"9","author":"Boussageon R.","year":"2012","unstructured":"Boussageon R.; Supper I.; Bejan-Angoulvant T.; Kellou N.; Cucherat M.; Boissel J.P.; Kassai B.; Moreau A.; Gueyffier F.; Cornu C.; Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med 2012,9(4),e1001204","journal-title":"PLoS Med"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1007\/s00125-017-4337-9","volume":"60","author":"Griffin S.J.","year":"2017","unstructured":"Griffin S.J.; Leaver J.K.; Irving G.J.; Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia 2017,60(9),1620-1629","journal-title":"Diabetologia"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1001\/archinternmed.2010.409","volume":"170","author":"Roussel R.","year":"2010","unstructured":"Roussel R.; Travert F.; Pasquet B.; Wilson P.W.; Smith S.C.; Goto S.; Ravaud P.; Marre M.; Porath A.; Bhatt D.L.; Steg P.G.; Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators2010,170(21),1892-1899","journal-title":"Arch Intern Med"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1001\/jama.295.2.180","volume":"295","author":"Bhatt D.L.","year":"2006","unstructured":"Bhatt D.L.; Steg P.G.; Ohman E.M.; Hirsch A.T.; Ikeda Y.; Mas J.L.; Goto S.; Liau C.S.; Richard A.J.; R\u00f6ther J.; Wilson P.W.; International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006,295(2),180-189","journal-title":"JAMA"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12933-019-0900-7","volume":"18","author":"Han Y.","year":"2019","unstructured":"Han Y.; Xie H.; Liu Y.; Gao P.; Yang X.; Shen Z.; Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol 2019,18(1),96","journal-title":"Cardiovasc Diabetol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S2213-8587(17)30194-8","volume":"5","author":"Petrie J.R.","year":"2017","unstructured":"Petrie J.R.; Chaturvedi N.; Ford I.; Brouwers M.C.G.J.; Greenlaw N.; Tillin T.; Hramiak I.; Hughes A.D.; Jenkins A.J.; Klein B.E.K.; Klein R.; Ooi T.C.; Rossing P.; Stehouwer C.D.A.; Sattar N.; Colhoun H.M.; Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol REMOVAL Study Group2017,5(8),597-609","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.2337\/diacare.28.10.2345","volume":"28","author":"Eurich D.T.","year":"2005","unstructured":"Eurich D.T.; Majumdar S.R.; McAlister F.A.; Tsuyuki R.T.; Johnson J.A.; Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005,28(10),2345-2351","journal-title":"Diabetes Care"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.2337\/dc09-2227","volume":"33","author":"MacDonald M.R.","year":"2010","unstructured":"MacDonald M.R.; Eurich D.T.; Majumdar S.R.; Lewsey J.D.; Bhagra S.; Jhund P.S.; Petrie M.C.; McMurray J.J.; Petrie J.R.; McAlister F.A.; Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. Diabetes Care 2010,33(6),1213-1218","journal-title":"Diabetes Care"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.cardfail.2009.10.022","volume":"16","author":"Shah D.D.","year":"2010","unstructured":"Shah D.D.; Fonarow G.C.; Horwich T.B.; Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. J Card Fail 2010,16(3),200-206","journal-title":"J Card Fail"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.bioorg.2018.02.009","volume":"77","author":"Nanjan M.J.","year":"2018","unstructured":"Nanjan M.J.; Mohammed M.; Prashantha Kumar B.R.; Chandrasekar M.J.N.; Thiazolidinediones as antidiabetic agents: A critical review. Bioorg Chem 2018,77,548-567","journal-title":"Bioorg Chem"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1007\/s13300-018-0493-2","volume":"9","author":"Cai X.","year":"2018","unstructured":"Cai X.; Gao X.; Yang W.; Han X.; Ji L.; Efficacy and Safety of Initial Combination Therapy in Treatment-Na\u00efve Type 2 Diabetes Patients: A Systematic Review and Meta-analysis. Diabetes Ther 2018,9(5),1995-2014","journal-title":"Diabetes Ther"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"e013927","DOI":"10.1136\/bmjopen-2016-013927","volume":"7","author":"Liao H.W.","year":"2017","unstructured":"Liao H.W.; Saver J.L.; Wu Y.L.; Chen T.H.; Lee M.; Ovbiagele B.; Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ Open 2017,7(1),e013927","journal-title":"BMJ Open"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s11892-019-1270-y","volume":"19","author":"Lebovitz H.E.","year":"2019","unstructured":"Lebovitz H.E.; Thiazolidinediones: the Forgotten Diabetes Medications. Curr Diab Rep 2019,19(12),151","journal-title":"Curr Diab Rep"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1056\/NEJMoa072761","volume":"356","author":"Nissen S.E.","year":"2007","unstructured":"Nissen S.E.; Wolski K.; Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007,356(24),2457-2471","journal-title":"N Engl J Med"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1001\/jama.298.10.1189","volume":"298","author":"Singh S.","year":"2007","unstructured":"Singh S.; Loke Y.K.; Furberg C.D.; Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007,298(10),1189-1195","journal-title":"JAMA"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","volume":"373","author":"Home P.D.","year":"2009","unstructured":"Home P.D.; Pocock S.J.; Beck-Nielsen H.; Curtis P.S.; Gomis R.; Hanefeld M.; Jones N.P.; Komajda M.; McMurray J.J.; Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet RECORD Study Team2009,373(9681),2125-2135","journal-title":"Lancet"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1001\/archinternmed.2010.207","volume":"170","author":"Nissen S.E.","year":"2010","unstructured":"Nissen S.E.; Wolski K.; Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010,170(14),1191-1201","journal-title":"Arch Intern Med"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jama.2010.920","volume":"304","author":"Graham D.J.","year":"2010","unstructured":"Graham D.J.; Ouellet-Hellstrom R.; MaCurdy T.E.; Ali F.; Sholley C.; Worrall C.; Kelman J.A.; Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010,304(4),411-418","journal-title":"JAMA"},{"key":"ref=92","year":"2010","unstructured":"European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim 2010"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/pds.3736","volume":"24","author":"Stone J.C.","year":"2015","unstructured":"Stone J.C.; Furuya-Kanamori L.; Barendregt J.J.; Doi S.A.; Was there really any evidence that rosiglitazone increased the risk of myocardial infarction or death from cardiovascular causes? Pharmacoepidemiol Drug Saf 2015,24(3),223-227","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12933-017-0617-4","volume":"16","author":"de Jong M.","year":"2017","unstructured":"de Jong M.; van der Worp H.B.; van der Graaf Y.; Visseren F.L.J.; Westerink J.; Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials. Cardiovasc Diabetol 2017,16(1),134","journal-title":"Cardiovasc Diabetol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2174\/1568026620666191224141617","volume":"20","author":"Lv W.","year":"2020","unstructured":"Lv W.; Wang X.; Xu Q.; Lu W.; Mechanisms and Characteristics of Sulfonylureas and Glinides. Curr Top Med Chem 2020,20(1),37-56","journal-title":"Curr Top Med Chem"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s00125-013-2856-6","volume":"56","author":"Hirst J.A.","year":"2013","unstructured":"Hirst J.A.; Farmer A.J.; Dyar A.; Lung T.W.; Stevens R.J.; Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis. Diabetologia 2013,56(5),973-984","journal-title":"Diabetologia"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"e0217701","DOI":"10.1371\/journal.pone.0217701","volume":"14","author":"Grenet G.","year":"2019","unstructured":"Grenet G.; Ribault S.; Nguyen G.B.; Glais F.; Metge A.; Linet T.; Kassai-Koupai B.; Cornu C.; Bejan-Angoulvant T.; Erpeldinger S.; Boussageon R.; Gouraud A.; Bonnet F.; Cucherat M.; Moulin P.; Gueyffier F.; GLUcose COntrol Safety","journal-title":"PLoS One"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1503\/cmaj.051237","volume":"174","author":"Bell DSH","year":"2006","unstructured":"Bell DSH; Do sulfonylurea drugs increase the risk of cardiac events? 2006,174(2),185-6"},{"key":"ref=99","first-page":"789","volume":"19","author":"Meinert C.L.","year":"1970","unstructured":"Meinert C.L.; Knatterud G.L.; Prout T.E.; Klimt C.R.; A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970,19(Suppl.),789-830","journal-title":"Diabetes"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1353\/pbm.2004.0071","volume":"47","author":"Schwartz T.B.","year":"2004","unstructured":"Schwartz T.B.; Meinert C.L.; The UGDP controversy: thirty-four years of contentious ambiguity laid to rest. Perspect Biol Med 2004,47(4),564-574","journal-title":"Perspect Biol Med"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/dom.12821","volume":"19","author":"Bain S.","year":"2017","unstructured":"Bain S.; Druyts E.; Balijepalli C.; Baxter C.A.; Currie C.J.; Das R.; Donnelly R.; Khunti K.; Langerman H.; Leigh P.; Siliman G.; Thorlund K.; Toor K.; Vora J.; Mills E.J.; Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data. Diabetes Obes Metab 2017,19(3),329-335","journal-title":"Diabetes Obes Metab"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S2213-8587(14)70213-X","volume":"3","author":"Simpson S.H.","year":"2015","unstructured":"Simpson S.H.; Lee J.; Choi S.; Vandermeer B.; Abdelmoneim A.S.; Featherstone T.R.; Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol 2015,3(1),43-51","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.amjcard.2019.10.025","volume":"124","author":"Nassif M.E.","year":"2019","unstructured":"Nassif M.E.; Kosiborod M.; A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes. Am J Cardiol 2019,124(Suppl. 1),S12-S19","journal-title":"Am J Cardiol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S2213-8587(17)30317-0","volume":"5","author":"Vaccaro O.","year":"2017","unstructured":"Vaccaro O.; Masulli M.; Nicolucci A.; Bonora E.; Del Prato S.; Maggioni A.P.; Rivellese A.A.; Squatrito S.; Giorda C.B.; Sesti G.; Mocarelli P.; Lucisano G.; Sacco M.; Signorini S.; Cappellini F.; Perriello G.; Babini A.C.; Lapolla A.; Gregori G.; Giordano C.; Corsi L.; Buzzetti R.; Clemente G.; Di Cianni G.; Iannarelli R.; Cordera R.; La Macchia O.; Zamboni C.; Scaranna C.; Boemi M.; Iovine C.; Lauro D.; Leotta S.; Dall\u2019Aglio E.; Cannarsa E.; Tonutti L.; Pugliese G.; Bossi A.C.; Anichini R.; Dotta F.; Di Benedetto A.; Citro G.; Antenucci D.; Ricci L.; Giorgino F.; Santini C.; Gnasso A.; De Cosmo S.; Zavaroni D.; Vedovato M.; Consoli A.; Calabrese M.; di Bartolo P.; Fornengo P.; Riccardi G.; Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group2017,5(11),887-897","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.mce.2008.08.012","volume":"297","author":"Holst J.J.","year":"2009","unstructured":"Holst J.J.; Vilsb\u00f8ll T.; Deacon C.F.; The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009,297(1-2),127-136","journal-title":"Mol Cell Endocrinol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41574-018-0016-2","volume":"14","author":"Andersen A.","year":"2018","unstructured":"Andersen A.; Lund A.; Knop F.K.; Vilsb\u00f8ll T.; Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol 2018,14(7),390-403","journal-title":"Nat Rev Endocrinol"},{"key":"ref=107","year":"2017","unstructured":"New Drugs for Type 2 Diabetes: Second-Line Therapy \u2014 Science Report Ottawa, ON Canadian Agency for Drugs and Technologies in Health 2017","journal-title":"New Drugs for Type 2 Diabetes: Second-Line Therapy \u2014 Science Report Ottawa, ON Canadian Agency for Drugs and Technologies in Health"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/pds.3586","volume":"23","author":"Liu X.","year":"2014","unstructured":"Liu X.; Xiao Q.; Zhang L.; Yang Q.; Liu X.; Xu L.; Cheng W.; The long-term efficacy and safety of DPP-IV inhibitors monotherapy and in combination with metformin in 18,980 patients with type-2 diabetes mellitus--a meta-analysis. Pharmacoepidemiol Drug Saf 2014,23(7),687-698","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref=109","author":"Abd El Aziz M.","year":"2019","unstructured":"Abd El Aziz M.; Cahyadi O.; Meier J.J.; Schmidt W.E.; Nauck M.A.; Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Diabetes Obes Metab 2019","journal-title":"Diabetes Obes Metab"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.jcjd.2019.04.003","volume":"43","author":"Alfayez O.M.","year":"2019","unstructured":"Alfayez O.M.; Almutairi A.R.; Aldosari A.; Al Yami M.S.; Update on Cardiovascular Safety of Incretin-Based Therapy in Adults With Type 2 Diabetes Mellitus: A Meta-Analysis of Cardiovascular Outcome Trials. Can J Diabetes 2019,43(7),538-545.e2","journal-title":"Can J Diabetes"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"Scirica B.M.","year":"2013","unstructured":"Scirica B.M.; Bhatt D.L.; Braunwald E.; Steg P.G.; Davidson J.; Hirshberg B.; Ohman P.; Frederich R.; Wiviott S.D.; Hoffman E.B.; Cavender M.A.; Udell J.A.; Desai N.R.; Mosenzon O.; McGuire D.K.; Ray K.K.; Leiter L.A.; Raz I.; Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013,369(14),1317-1326","journal-title":"N Engl J Med"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"Green J.B.","year":"2015","unstructured":"Green J.B.; Bethel M.A.; Armstrong P.W.; Buse J.B.; Engel S.S.; Garg J.; Josse R.; Kaufman K.D.; Koglin J.; Korn S.; Lachin J.M.; McGuire D.K.; Pencina M.J.; Standl E.; Stein P.P.; Suryawanshi S.; Van de Werf F.; Peterson E.D.; Holman R.R.; Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015,373(3),232-242","journal-title":"N Engl J Med"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2018.18269","volume":"321","author":"Rosenstock J.","year":"2019","unstructured":"Rosenstock J.; Perkovic V.; Johansen O.E.; Cooper M.E.; Kahn S.E.; Marx N.; Alexander J.H.; Pencina M.; Toto R.D.; Wanner C.; Zinman B.; Woerle H.J.; Baanstra D.; Pfarr E.; Schnaidt S.; Meinicke T.; George J.T.; von Eynatten M.; McGuire D.K.; Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The carmelina randomized Clinical Trial. JAMA CARMELINA Investigators2019,321(1),69-79","journal-title":"JAMA"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"White W.B.","year":"2013","unstructured":"White W.B.; Cannon C.P.; Heller S.R.; Nissen S.E.; Bergenstal R.M.; Bakris G.L.; Perez A.T.; Fleck P.R.; Mehta C.R.; Kupfer S.; Wilson C.; Cushman W.C.; Zannad F.; Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013,369(14),1327-1335","journal-title":"N Engl J Med"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","volume":"385","author":"Zannad F.","year":"2015","unstructured":"Zannad F.; Cannon C.P.; Cushman W.C.; Bakris G.L.; Menon V.; Perez A.T.; Fleck P.R.; Mehta C.R.; Kupfer S.; Wilson C.; Lam H.; White W.B.; Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 2015,385(9982),2067-2076","journal-title":"Lancet"},{"key":"ref=116","author":"Food U","year":"2016","unstructured":"Food U; Administration D.; FDA Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin 2016"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1111\/dom.12951","volume":"19","author":"Williams R.","year":"2017","unstructured":"Williams R.; de Vries F.; Kothny W.; Serban C.; Lopez-Leon S.; Chu C.; Schlienger R.; Cardiovascular safety of vildagliptin in patients with type 2 diabetes: A European multi-database, non-interventional post-authorization safety study. Diabetes Obes Metab 2017,19(10),1473-1478","journal-title":"Diabetes Obes Metab"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/dom.12849","volume":"19","author":"Htike Z.Z.","year":"2017","unstructured":"Htike Z.Z.; Zaccardi F.; Papamargaritis D.; Webb D.R.; Khunti K.; Davies M.J.; Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab 2017,19(4),524-536","journal-title":"Diabetes Obes Metab"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1080\/17512433.2018.1534201","volume":"11","author":"Coon S.A.","year":"2018","unstructured":"Coon S.A.; Crannage E.F.; Kerwin L.C.; Guyton J.E.; Semaglutide once-weekly: improved efficacy with a new safety warning. Expert Rev Clin Pharmacol 2018,11(11),1061-1072","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.diabres.2019.06.009","volume":"154","author":"Maiorino M.I.","year":"2019","unstructured":"Maiorino M.I.; Chiodini P.; Bellastella G.; Scappaticcio L.; Longo M.; Giugliano D.; Esposito K.; The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 2019,154,101-115","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1056\/NEJMp1314078","volume":"370","author":"Egan A.G.","year":"2014","unstructured":"Egan A.G.; Blind E.; Dunder K.; de Graeff P.A.; Hummer B.T.; Bourcier T.; Rosebraugh C.; Pancreatic safety of incretin-based drugs--FDA and EMA assessment. N Engl J Med 2014,370(9),794-797","journal-title":"N Engl J Med"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1111\/dom.12926","volume":"19","author":"Monami M.","year":"2017","unstructured":"Monami M.; Nreu B.; Scatena A.; Cresci B.; Andreozzi F.; Sesti G.; Mannucci E.; Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials. Diabetes Obes Metab 2017,19(9),1233-1241","journal-title":"Diabetes Obes Metab"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"Marso S.P.","year":"2016","unstructured":"Marso S.P.; Bain S.C.; Consoli A.; Eliaschewitz F.G.; J\u00f3dar E.; Leiter L.A.; Lingvay I.; Rosenstock J.; Seufert J.; Warren M.L.; Woo V.; Hansen O.; Holst A.G.; Pettersson J.; Vilsb\u00f8ll T.; Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med SUSTAIN-6 Investigators2016,375(19),1834-1844","journal-title":"N Engl J Med"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"Husain M.","year":"2019","unstructured":"Husain M.; Birkenfeld A.L.; Donsmark M.; Dungan K.; Eliaschewitz F.G.; Franco D.R.; Jeppesen O.K.; Lingvay I.; Mosenzon O.; Pedersen S.D.; Tack C.J.; Thomsen M.; Vilsb\u00f8ll T.; Warren M.L.; Bain S.C.; Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med PIONEER 6 Investigators2019,381(9),841-851","journal-title":"N Engl J Med"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"Kristensen S.L.","year":"2019","unstructured":"Kristensen S.L.; R\u00f8rth R.; Jhund P.S.; Docherty K.F.; Sattar N.; Preiss D.; K\u00f8ber L.; Petrie M.C.; McMurray J.J.V.; Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019,7(10),776-785","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1111\/dom.13847","volume":"21","author":"Giugliano D.","year":"2019","unstructured":"Giugliano D.; Maiorino M.I.; Bellastella G.; Longo M.; Chiodini P.; Esposito K.; GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials. Diabetes Obes Metab 2019,21(11),2576-2580","journal-title":"Diabetes Obes Metab"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"Pfeffer M.A.","year":"2015","unstructured":"Pfeffer M.A.; Claggett B.; Diaz R.; Dickstein K.; Gerstein H.C.; K\u00f8ber L.V.; Lawson F.C.; Ping L.; Wei X.; Lewis E.F.; Maggioni A.P.; McMurray J.J.; Probstfield J.L.; Riddle M.C.; Solomon S.D.; Tardif J.C.; Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med ELIXA Investigators2015,373(23),2247-2257","journal-title":"N Engl J Med"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"Marso S.P.","year":"2016","unstructured":"Marso S.P.; Daniels G.H.; Brown-Frandsen K.; Kristensen P.; Mann J.F.; Nauck M.A.; Nissen S.E.; Pocock S.; Poulter N.R.; Ravn L.S.; Steinberg W.M.; Stockner M.; Zinman B.; Bergenstal R.M.; Buse J.B.; Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med LEADER Steering Committee LEADER Trial Investigators2016,375(4),311-322","journal-title":"N Engl J Med"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"Holman R.R.","year":"2017","unstructured":"Holman R.R.; Bethel M.A.; Mentz R.J.; Thompson V.P.; Lokhnygina Y.; Buse J.B.; Chan J.C.; Choi J.; Gustavson S.M.; Iqbal N.; Maggioni A.P.; Marso S.P.; \u00d6hman P.; Pagidipati N.J.; Poulter N.; Ramachandran A.; Zinman B.; Hernandez A.F.; Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med EXSCEL Study Group2017,377(13),1228-1239","journal-title":"N Engl J Med"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"Hernandez A.F.","year":"2018","unstructured":"Hernandez A.F.; Green J.B.; Janmohamed S.; D\u2019Agostino R.B.; Granger C.B.; Jones N.P.; Leiter L.A.; Rosenberg A.E.; Sigmon K.N.; Somerville M.C.; Thorpe K.M.; McMurray J.J.V.; Del Prato S.; Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018,392(10157),1519-1529","journal-title":"Lancet"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"Gerstein H.C.","year":"2019","unstructured":"Gerstein H.C.; Colhoun H.M.; Dagenais G.R.; Diaz R.; Lakshmanan M.; Pais P.; Probstfield J.; Riesmeyer J.S.; Riddle M.C.; Ryd\u00e9n L.; Xavier D.; Atisso C.M.; Dyal L.; Hall S.; Rao-Melacini P.; Wong G.; Avezum A.; Basile J.; Chung N.; Conget I.; Cushman W.C.; Franek E.; Hancu N.; Hanefeld M.; Holt S.; Jansky P.; Keltai M.; Lanas F.; Leiter L.A.; Lopez-Jaramillo P.; Cardona Munoz E.G.; Pirags V.; Pogosova N.; Raubenheimer P.J.; Shaw J.E.; Sheu W.H.; Temelkova-Kurktschiev T.; Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019,394(10193),121-130","journal-title":"Lancet"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"2047487320903638","DOI":"10.1177\/2047487320903638","author":"Pulipati V.P.","year":"2020","unstructured":"Pulipati V.P.; Ravi V.; Pulipati P.; Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Eur J Prev Cardiol 2020,2047487320903638","journal-title":"Eur J Prev Cardiol"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"ehaa082","DOI":"10.1093\/eurheartj\/ehaa082","author":"Marsico F.","year":"2020","unstructured":"Marsico F.; Paolillo S.; Gargiulo P.; Bruzzese D.; Dell\u2019Aversana S.; Esposito I.; Renga F.; Esposito L.; Marciano C.; Dellegrottaglie S.; Iesu I.; Perrone Filardi P.; Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials. Eur Heart J 2020,ehaa082","journal-title":"Eur Heart J"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jama.2016.10260","volume":"316","author":"Margulies K.B.","year":"2016","unstructured":"Margulies K.B.; Hernandez A.F.; Redfield M.M.; Givertz M.M.; Oliveira G.H.; Cole R.; Mann D.L.; Whellan D.J.; Kiernan M.S.; Felker G.M.; McNulty S.E.; Anstrom K.J.; Shah M.R.; Braunwald E.; Cappola T.P.; Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA NHLBI Heart Failure Clinical Research Network2016,316(5),500-508","journal-title":"JAMA"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ejhf.657","volume":"19","author":"Jorsal A.","year":"2017","unstructured":"Jorsal A.; Kistorp C.; Holmager P.; Tougaard R.S.; Nielsen R.; H\u00e4nselmann A.; Nilsson B.; M\u00f8ller J.E.; Hjort J.; Rasmussen J.; Boesgaard T.W.; Schou M.; Videbaek L.; Gustafsson I.; Flyvbjerg A.; Wiggers H.; Tarnow L.; Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 2017,19(1),69-77","journal-title":"Eur J Heart Fail"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s13300-017-0282-3","volume":"8","author":"Wang W.","year":"2017","unstructured":"Wang W.; Liu H.; Xiao S.; Liu S.; Li X.; Yu P.; Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Diabetes Ther 2017,8(4),727-738","journal-title":"Diabetes Ther"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.2337\/dc16-0690","volume":"39","author":"Ahr\u00e9n B.","year":"2016","unstructured":"Ahr\u00e9n B.; Hirsch I.B.; Pieber T.R.; Mathieu C.; G\u00f3mez-Peralta F.; Hansen T.K.; Philotheou A.; Birch S.; Christiansen E.; Jensen T.J.; Buse J.B.; Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial. Diabetes Care ADJUNCT TWO Investigators2016,39(10),1693-1701","journal-title":"Diabetes Care"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.2337\/dc16-0691","volume":"39","author":"Mathieu C.","year":"2016","unstructured":"Mathieu C.; Zinman B.; Hemmingsson J.U.; Woo V.; Colman P.; Christiansen E.; Linder M.; Bode B.; Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. Diabetes Care ADJUNCT ONE Investigators2016,39(10),1702-1710","journal-title":"Diabetes Care"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"e0166125","DOI":"10.1371\/journal.pone.0166125","volume":"11","author":"Storgaard H.","year":"2016","unstructured":"Storgaard H.; Gluud L.L.; Bennett C.; Gr\u00f8ndahl M.F.; Christensen M.B.; Knop F.K.; Vilsb\u00f8ll T.; Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. PLoS One 2016,11(11),e0166125","journal-title":"PLoS One"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"Zelniker T.A.","year":"2019","unstructured":"Zelniker T.A.; Wiviott S.D.; Raz I.; Im K.; Goodrich E.L.; Bonaca M.P.; Mosenzon O.; Kato E.T.; Cahn A.; Furtado R.H.M.; Bhatt D.L.; Leiter L.A.; McGuire D.K.; Wilding J.P.H.; Sabatine M.S.; SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019,393(10166),31-39","journal-title":"Lancet"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1038\/s41598-017-02733-w","volume":"7","author":"Liu J.","year":"2017","unstructured":"Liu J.; Li L.; Li S.; Jia P.; Deng K.; Chen W.; Sun X.; Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Sci Rep 2017,7(1),2824","journal-title":"Sci Rep"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"Zinman B.","year":"2015","unstructured":"Zinman B.; Wanner C.; Lachin J.M.; Fitchett D.; Bluhmki E.; Hantel S.; Mattheus M.; Devins T.; Johansen O.E.; Woerle H.J.; Broedl U.C.; Inzucchi S.E.; Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med EMPA-REG OUTCOME Investigators2015,373(22),2117-2128","journal-title":"N Engl J Med"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"Neal B.","year":"2017","unstructured":"Neal B.; Perkovic V.; Mahaffey K.W.; de Zeeuw D.; Fulcher G.; Erondu N.; Shaw W.; Law G.; Desai M.; Matthews D.R.; Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017,377(7),644-657","journal-title":"N Engl J Med"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"Perkovic V.","year":"2019","unstructured":"Perkovic V.; Jardine M.J.; Neal B.; Bompoint S.; Heerspink H.J.L.; Charytan D.M.; Edwards R.; Agarwal R.; Bakris G.; Bull S.; Cannon C.P.; Capuano G.; Chu P.L.; de Zeeuw D.; Greene T.; Levin A.; Pollock C.; Wheeler D.C.; Yavin Y.; Zhang H.; Zinman B.; Meininger G.; Brenner B.M.; Mahaffey K.W.; Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med CREDENCE Trial Investigators2019,380(24),2295-2306","journal-title":"N Engl J Med"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"Wiviott S.D.","year":"2019","unstructured":"Wiviott S.D.; Raz I.; Bonaca M.P.; Mosenzon O.; Kato E.T.; Cahn A.; Silverman M.G.; Zelniker T.A.; Kuder J.F.; Murphy S.A.; Bhatt D.L.; Leiter L.A.; McGuire D.K.; Wilding J.P.H.; Ruff C.T.; Gause-Nilsson I.A.M.; Fredriksson M.; Johansson P.A.; Langkilde A.M.; Sabatine M.S.; Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med DECLARE\u2013TIMI 58 Investigators2019,380(4),347-357","journal-title":"N Engl J Med"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","volume":"137","author":"Mahaffey K.W.","year":"2018","unstructured":"Mahaffey K.W.; Neal B.; Perkovic V.; de Zeeuw D.; Fulcher G.; Erondu N.; Shaw W.; Fabbrini E.; Sun T.; Li Q.; Desai M.; Matthews D.R.; Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation CANVAS Program Collaborative Group2018,137(4),323-334","journal-title":"Circulation"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1475-2840-13-102","volume":"13","author":"Zinman B.","year":"2014","unstructured":"Zinman B.; Inzucchi S.E.; Lachin J.M.; Wanner C.; Ferrari R.; Fitchett D.; Bluhmki E.; Hantel S.; Kempthorne-Rawson J.; Newman J.; Johansen O.E.; Woerle H.J.; Broedl U.C.; Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME\u2122). Cardiovasc Diabetol 2014,13,102","journal-title":"Cardiovasc Diabetol"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"Kosiborod M.","year":"2017","unstructured":"Kosiborod M.; Cavender M.A.; Fu A.Z.; Wilding J.P.; Khunti K.; Holl R.W.; Norhammar A.; Birkeland K.I.; J\u00f8rgensen M.E.; Thuresson M.; Arya N.; Bodeg\u00e5rd J.; Hammar N.; Fenici P.; Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation CVD-REAL Investigators and Study Group*2017,136(3),249-259","journal-title":"Circulation"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1016\/j.jacc.2018.03.009","volume":"71","author":"Kosiborod M.","year":"2018","unstructured":"Kosiborod M.; Lam C.S.P.; Kohsaka S.; Kim D.J.; Karasik A.; Shaw J.; Tangri N.; Goh S.Y.; Thuresson M.; Chen H.; Surmont F.; Hammar N.; Fenici P.; Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study. J Am Coll Cardiol CVD-REAL Investigators and Study Group2018,71(23),2628-2639","journal-title":"J Am Coll Cardiol"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/ejhf.1432","volume":"21","author":"McMurray J.J.V.","year":"2019","unstructured":"McMurray J.J.V.; DeMets D.L.; Inzucchi S.E.; K\u00f8ber L.; Kosiborod M.N.; Langkilde A.M.; Martinez F.A.; Bengtsson O.; Ponikowski P.; Sabatine M.S.; Sj\u00f6strand M.; Solomon S.D.; A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail 2019,21(5),665-675","journal-title":"Eur J Heart Fail"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1002\/ejhf.1548","volume":"21","author":"McMurray J.J.V.","year":"2019","unstructured":"McMurray J.J.V.; DeMets D.L.; Inzucchi S.E.; K\u00f8ber L.; Kosiborod M.N.; Langkilde A.M.; Martinez F.A.; Bengtsson O.; Ponikowski P.; Sabatine M.S.; Sj\u00f6strand M.; Solomon S.D.; The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. Eur J Heart Fail DAPA-HF Committees and Investigators2019,21(11),1402-1411","journal-title":"Eur J Heart Fail"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"McMurray J.J.V.","year":"2019","unstructured":"McMurray J.J.V.; Solomon S.D.; Inzucchi S.E.; K\u00f8ber L.; Kosiborod M.N.; Martinez F.A.; Ponikowski P.; Sabatine M.S.; Anand I.S.; B\u011blohl\u00e1vek J.; B\u00f6hm M.; Chiang C.E.; Chopra V.K.; de Boer R.A.; Desai A.S.; Diez M.; Drozdz J.; Duk\u00e1t A.; Ge J.; Howlett J.G.; Katova T.; Kitakaze M.; Ljungman C.E.A.; Merkely B.; Nicolau J.C.; O\u2019Meara E.; Petrie M.C.; Vinh P.N.; Schou M.; Tereshchenko S.; Verma S.; Held C.; DeMets D.L.; Docherty K.F.; Jhund P.S.; Bengtsson O.; Sj\u00f6strand M.; Langkilde A.M.; Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med DAPA-HF Trial Committees and Investigators2019,381(21),1995-2008","journal-title":"N Engl J Med"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1002\/ejhf.1596","volume":"21","author":"Anker S.D.","year":"2019","unstructured":"Anker S.D.; Butler J.; Filippatos G.S.; Jamal W.; Salsali A.; Schnee J.; Kimura K.; Zeller C.; George J.; Brueckmann M.; Zannad F.; Packer M.; Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. Eur J Heart Fail 2019,21(10),1279-1287","journal-title":"Eur J Heart Fail"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/ejhf.1536","volume":"21","author":"Packer M.","year":"2019","unstructured":"Packer M.; Butler J.; Filippatos G.S.; Jamal W.; Salsali A.; Schnee J.; Kimura K.; Zeller C.; George J.; Brueckmann M.; Anker S.D.; Zannad F.; Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. Eur J Heart Fail EMPEROR-Reduced Trial Committees and Investigators2019,21(10),1270-1278","journal-title":"Eur J Heart Fail"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"532","DOI":"10.2337\/dc15-1995","volume":"39","author":"Peters A.L.","year":"2016","unstructured":"Peters A.L.; Henry R.R.; Thakkar P.; Tong C.; Alba M.; Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes. Diabetes Care 2016,39(4),532-538","journal-title":"Diabetes Care"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.2337\/dc15-1730","volume":"38","author":"Henry R.R.","year":"2015","unstructured":"Henry R.R.; Thakkar P.; Tong C.; Polidori D.; Alba M.; Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes. Diabetes Care 2015,38(12),2258-2265","journal-title":"Diabetes Care"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1007\/s40265-019-01213-x","volume":"79","author":"Paik J.","year":"2019","unstructured":"Paik J.; Blair H.A.; Dapagliflozin: A Review in Type 1 Diabetes. Drugs 2019,79(17),1877-1884","journal-title":"Drugs"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.2337\/dc18-1087","volume":"41","author":"Dandona P.","year":"2018","unstructured":"Dandona P.; Mathieu C.; Phillip M.; Hansen L.; Tsch\u00f6pe D.; Thor\u00e9n F.; Xu J.; Langkilde A.M.; Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. Diabetes Care DEPICT-1 Investigators2018,41(12),2552-2559","journal-title":"Diabetes Care"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.2147\/DMSO.S194688","volume":"12","author":"Mathieu C.","year":"2019","unstructured":"Mathieu C.; Van Den Mooter L.; Eeckhout B.; Empagliflozin in type 1 diabetes. Diabetes Metab Syndr Obes 2019,12,1555-1561","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.2337\/dc18-0623","volume":"41","author":"Mathieu C.","year":"2018","unstructured":"Mathieu C.; Dandona P.; Gillard P.; Senior P.; Hasslacher C.; Araki E.; Lind M.; Bain S.C.; Jabbour S.; Arya N.; Hansen L.; Thor\u00e9n F.; Langkilde A.M.; Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. Diabetes Care DEPICT-2 Investigators2018,41(9),1938-1946","journal-title":"Diabetes Care"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/dom.12494","volume":"17","author":"Pieber T.R.","year":"2015","unstructured":"Pieber T.R.; Famulla S.; Eilbracht J.; Cescutti J.; Soleymanlou N.; Johansen O.E.; Woerle H.J.; Broedl U.C.; Kaspers S.; Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab 2015,17(10),928-935","journal-title":"Diabetes Obes Metab"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.2337\/dc18-1749","volume":"41","author":"Rosenstock J.","year":"2018","unstructured":"Rosenstock J.; Marquard J.; Laffel L.M.; Neubacher D.; Kaspers S.; Cherney D.Z.; Zinman B.; Skyler J.S.; George J.; Soleymanlou N.; Perkins B.A.; Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. Diabetes Care 2018,41(12),2560-2569","journal-title":"Diabetes Care"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1093\/eurheartj\/ehm519","volume":"29","author":"Anselmino M.","year":"2008","unstructured":"Anselmino M.; \u00d6hrvik J.; Malmberg K.; Standl E.; Ryd\u00e9n L.; Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart J 2008,29(2),177-184","journal-title":"Eur Heart J"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ahj.2004.07.005","volume":"149","author":"Smooke S.","year":"2005","unstructured":"Smooke S.; Horwich T.B.; Fonarow G.C.; Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J 2005,149(1),168-174","journal-title":"Am Heart J"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.pcad.2017.09.001","volume":"60","author":"Herman M.E.","year":"2017","unstructured":"Herman M.E.; O\u2019Keefe J.H.; Bell D.S.H.; Schwartz S.S.; Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes. Prog Cardiovasc Dis 2017,60(3),422-434","journal-title":"Prog Cardiovasc Dis"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"e006341","DOI":"10.1136\/bmjopen-2014-006341","volume":"5","author":"Price H.I.","year":"2015","unstructured":"Price H.I.; Agnew M.D.; Gamble J-M.; Comparative cardiovascular morbidity and mortality in patients taking different insulin regimens for type 2 diabetes: a systematic review. BMJ Open 2015,5(3),e006341","journal-title":"BMJ Open"}],"container-title":["Current Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/185520","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/185520\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/185520","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T21:05:49Z","timestamp":1632517549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/185520\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":166,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574886315666200902154736","relation":{},"ISSN":["1574-8863"],"issn-type":[{"value":"1574-8863","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-04-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}